Antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy: fosfomycin trometamol, an attractive alternative

作者：Cai Tommaso^*; Gallelli Luca; Cocci Andrea; Tiscione Daniele; Verze Paolo; Lanciotti Michele; Vanacore Davide; Rizzo Michele; Gacci Mauro; Saleh Omar; Malossini Gianni; Liguori Giovanni; Trombetta Carlo; Rocco Damiano; Palmieri Alessandro; Bartoletti Riccardo; Carini Marco; Wagenlehner Florian M E; Naber Kurt; Mirone Vincenzo; Johansen Truls E Bjerklund

来源：World Journal of Urology, 2017, 35(2): 221-228.

DOI：10.1007/s00345-016-1867-6

• Prostate biopsy
• Fosfomycin trometamol
• Fluoroquinolone
• Prophylaxis
• Transrectal ultrasonography
• Urinary tract infection

To compare fosfomycin trometamol (FT) and ciprofloxacin (CIP) for antibiotic prophylaxis in transrectal prostate biopsy (TR-PB).
Data for 1109 patients (mean age 66.7 +/- 8.45) who underwent TR-PB between March to September 2015 in seven Italian urological institutions were retrospectively reviewed, of which 632 received FT (Group 1) and 477 received CIP (Group 2) for prophylaxis. We reviewed all urine culture results obtained after the procedure, all adverse drug reactions (ADRs) related to the drug and all febrile and/or symptomatic urinary tract infections (UTIs) occurring within 1 month after TR-PB. The rate of symptomatic UTIs and the rate of ADRs were considered the main outcome measures.
In the total study population, 72/1109 (6.5 %) patients experienced symptomatic UTIs and among these 11 (0.9 % of total) had urosepsis. Out of 72, 53 (73.6 %) symptomatic UTIs were caused by fluoroquinolone-resistant strains. Out of 632, 10 (1.6 %) patients in Group 1 and 62/477 (12.9 %) patients in Group 2 had symptomatic UTIs (p < 0.001); in particular, 2/632 (0.3 %) patients in Group 1 and 9/477 (1.8 %) patients in Group 2 had urosepsis (p < 0.001). No differences were reported in terms of adverse events (0.6 vs 0.4 %; p = 0.70). A Charlson comorbidity index <= 1 and type of antimicrobial prophylaxis (FT) were found to be associated with a lower probability of symptomatic UTIs in the multivariate model.
Antibiotic prophylaxis with FT for TR-PB had a lower rate of adverse events and a lower rate of symptomatic UTIs as compared with CIP. Fosfomycin trometamol appears as an attractive alternative prophylactic regimen in prostate biopsies.

• 出版日期2017-2